Switch theme
Sign up to access all valuation multiples
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
1998
25
Last FY Revenue $1.4M
Last FY EBITDA -$74.0M
$413M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Northwest Biotherapeutics achieved revenue of $1.4M and an EBITDA of -$74.0M.
Northwest Biotherapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Northwest Biotherapeutics valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $1.4M | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$74.0M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -5352% | XXX | XXX | XXX |
| EBIT | XXX | -$66.5M | XXX | XXX | XXX |
| EBIT Margin | XXX | -4812% | XXX | XXX | XXX |
| Net Profit | XXX | -$83.8M | XXX | XXX | XXX |
| Net Margin | XXX | -6062% | XXX | XXX | XXX |
| Net Debt | XXX | $60.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Northwest Biotherapeutics's stock price is $0.
Northwest Biotherapeutics has current market cap of $347M, and EV of $413M.
See Northwest Biotherapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $413M | $347M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Northwest Biotherapeutics has market cap of $347M and EV of $413M.
Northwest Biotherapeutics's trades at 298.8x EV/Revenue multiple, and -5.6x EV/EBITDA.
Equity research analysts estimate Northwest Biotherapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Northwest Biotherapeutics's P/E ratio is not available.
See valuation multiples for Northwest Biotherapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $347M | XXX | $347M | XXX | XXX | XXX |
| EV (current) | $413M | XXX | $413M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 298.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -5.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -6.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -4.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -7.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNorthwest Biotherapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $2.7M for the same period.
Northwest Biotherapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Northwest Biotherapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Northwest Biotherapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -5352% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2524% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 4912% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Northwest Biotherapeutics acquired XXX companies to date.
Last acquisition by Northwest Biotherapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Northwest Biotherapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Northwest Biotherapeutics founded? | Northwest Biotherapeutics was founded in 1998. |
| Where is Northwest Biotherapeutics headquartered? | Northwest Biotherapeutics is headquartered in United States of America. |
| How many employees does Northwest Biotherapeutics have? | As of today, Northwest Biotherapeutics has 25 employees. |
| Is Northwest Biotherapeutics publicy listed? | Yes, Northwest Biotherapeutics is a public company listed on PINX. |
| What is the stock symbol of Northwest Biotherapeutics? | Northwest Biotherapeutics trades under NWBO ticker. |
| When did Northwest Biotherapeutics go public? | Northwest Biotherapeutics went public in 2001. |
| Who are competitors of Northwest Biotherapeutics? | Similar companies to Northwest Biotherapeutics include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Northwest Biotherapeutics? | Northwest Biotherapeutics's current market cap is $347M |
| Is Northwest Biotherapeutics profitable? | Yes, Northwest Biotherapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
